This histogram enumerates side effects from a completed 2022 Phase 2 trial (NCT03003520) in the DUR + R-CHOP ARM group. Side effects include: Fatigue with 60%, Peripheral sensory neuropathy with 49%, Neutropenia with 47%, Nausea with 40%, Diarrhoea with 28%.
2 Treatment Groups
Durvalumab in combination with Tremelimumab (Cohort A dose)
1 of 2
Durvalumab in combination with Tremelimumab (Cohort B dose)
1 of 2
30 Total Participants · 2 Treatment Groups
Primary Treatment: Durvalumab · No Placebo Group · Phase 2
Durvalumab in combination with Tremelimumab (Cohort A dose)Experimental Group · 2 Interventions: Durvalumab, Tremelimumab (Cohort A dose) · Intervention Types: Drug, Drug
Durvalumab in combination with Tremelimumab (Cohort B dose)Experimental Group · 2 Interventions: Tremelimumab (Cohort B dose), Durvalumab · Intervention Types: Drug, Drug
Drug Approval Stage
How many patients have taken this drug
Screening: ~3 weeks
Reporting: 2 years
Who is running the clinical trial?
3,956 Previous Clinical Trials
91,808,882 Total Patients Enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
534 Previous Clinical Trials
31,082 Total Patients Enrolled
Ana De Jesus-Acosta, MDPrincipal InvestigatorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2 Previous Clinical Trials
121 Total Patients Enrolled
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have measurable disease.
You have no evidence of disease or have disease that is in a stable or controlled state.
You have a body weight of more than 30 kg.
Evidence of ascites with a score < 7.
You have adequate organ function defined by study-specified laboratory tests.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.